Establishment of a nomogram with EMP3 for predicting clinical outcomes in patients with glioma: A bi‐center study

Zhang, Anke; Xu, Houshi; Zhang, Zeyu; Liu, Yibo; Han, Xiaying; Yuan, Ling; Ni, Yunjia; Gao, Shiqi; Xu, Yuanzhi; Chen, Sheng; Jiang, Junkun; Chen, Yike; Zhang, Xiaotao; Lou, Meiqing; Zhang, Jianmin

doi:10.1111/cns.13701

Cited by 6 publications

(5 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Functional experiments showed that the knockdown of EMP3 significantly suppressed the malignant phenotype of tumor cells in terms of proliferation and migration. Consistent with other literature reports, Anke Zhang et al [ 32 ] demonstrated EMP3 as a novel predictor for clinical progression and clinical outcomes in glioma. However, what are the mechanisms and reasons behind it?…”

Section: Discussionsupporting

confidence: 89%

EMP3 as a prognostic biomarker correlates with EMT in GBM

Li,

Xia,

Zhao

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Glioblastoma (GBM) is the most aggressive malignant central nervous system tumor with a poor prognosis.The malignant transformation of glioma cells via epithelial-mesenchymal transition (EMT) has been observed as a main obstacle for glioblastoma treatment. Epithelial membrane protein 3 (EMP3) is significantly associated with the malignancy of GBM and the prognosis of patients. Therefore, exploring the possible mechanisms by which EMP3 promotes the growth of GBM has important implications for the treatment of GBM. Methods We performed enrichment and correlation analysis in 5 single-cell RNA sequencing datasets. Differential expression of EMP3 in gliomas, Kaplan–Meier survival curves, diagnostic accuracy and prognostic prediction were analyzed by bioinformatics in the China Glioma Genome Atlas (CGGA) database and The Cancer Genome Atlas (TCGA) database. EMP3-silenced U87 and U251 cell lines were obtained by transient transfection with siRNA. The effect of EMP3 on glioblastoma proliferation was examined using the CCK-8 assay. Transwell migration assay and wound healing assay were used to assess the effect of EMP3 on glioblastoma migration. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) and western blot were used to detect the mRNA and protein expression levels of EMT-related transcription factors and mesenchymal markers. Results EMP3 is a EMT associated gene in multiple types of malignant cancer and in high-grade glioblastoma. EMP3 is enriched in high-grade gliomas and isocitrate dehydrogenase (IDH) wild-type gliomas.EMP3 can be used as a specific biomarker for diagnosing glioma patients. It is also an independent prognostic factor for glioma patients' overall survival (OS). In addition, silencing EMP3 reduces the proliferation and migration of glioblastoma cells. Mechanistically, EMP3 enhances the malignant potential of tumor cells by promoting EMT. Conclusion EMP3 promotes the proliferation and migration of GBM cells, and the mechanism may be related to EMP3 promoting the EMT process in GBM; EMP3 may be an independent prognostic factor in GBM.

show abstract

Section: Discussionsupporting

confidence: 89%

EMP3 as a prognostic biomarker correlates with EMT in GBM

Li,

Xia,

Zhao

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…[ 17 ] However, EMP3 is a tumor-suppressor gene of low-grade glioma (LGG). [ 18 ] In our present study, a high EMP3 expression was associated with poor survival, confirming that EMP3 is an oncogene. Studies have shown that the APOBEC3C expression positively affects the invasiveness and prognosis of breast cancer, glioma, hepatocellular carcinoma, and prostate cancer.…”

Section: Discussionsupporting

confidence: 84%

Identification of a pyroptosis-related prognosis gene signature and its relationship with an immune microenvironment in gliomas

et al. 2022

View full text Add to dashboard Cite

Background: Glioma is the most common type of primary brain cancer, and the prognosis of most patients with glioma is poor. Pyroptosis is a newly discovered inflammatory programmed cell death. However, the expression of pyroptosis-related genes (PRGs) in glioma and its correlation with prognosis are unclear.Methods: 27 pyroptosis genes differentially expressed between glioma and adjacent normal tissues were identified. All glioma cases could be stratified into 2 subtypes based on these differentially expressed PRGs. The prognostic value of each PRG was evaluated to construct a prognostic model.Results: A novel 16-gene signature was constructed by using the least absolute shrinkage and selection operator Cox regression method. Then, patients with glioma were divided into low-and high-risk groups in the TCGA cohort. The survival rate of patients in the low-risk group was significantly higher than that in the high-risk group (P = .001). Patients with glioma from the Gene Expression Omnibus (GEO) cohort were stratified into 2 risk groups by using the median risk score. The overall survival (OS) of the low-risk group was longer than that of the high-risk group (P = .001). The risk score was considered an independent prognostic factor of the OS of patients with glioma. Gene ontology and Kyoto Encylopedia of Genes and Genomes analysis showed that the differentially expressed PRGs were mainly related to neutrophil activation involved in immune responses, focal adhesion, cell cycle, and p53 signaling pathway.Conclusion: PRGs could predict the prognosis of glioma and play significant roles in a tumor immune microenvironment.

show abstract

“…In previous studies, EMP3 [8] and CHI3L1 [24] were identified as novel independent predictors of clinical diagnosis, prognosis, and immune infiltration in glioma patients, respectively. In our study, we combined EMP3 and CHI3L1, which are correlated in glioma cells and can be combined as prognostic factors for patients with low-grade glioma.…”

Section: Discussionmentioning

confidence: 97%

“…Anke Zhang et al argued that aggressive treatment can impair a patient's quality of life and produce harmful adverse effects. Therefore, understanding the mechanisms underlying tumor progression is essential for disease management and prognosis prediction [8]. Gerber et al found that reduced mRNA expression levels of CHI3L1, EMP3, and other genes are associated with prolonged survival in glioma patients [9].…”

Section: Introductionmentioning

confidence: 99%

Epithelial Membrane Protein-3 and Chitinase-3-like Protein-1 as New Prognostic Predictors of Glioma, a Two-Gene Study

Shen,

Zhu,

Zhou

et al. 2023

Current Oncology

View full text Add to dashboard Cite

Background: Glioblastoma multiforme is the most common primary intracranial tumor, with a high degree of malignancy, poor therapeutic effect, and poor prognosis. According to previous studies, CHI3L1 and EMP3 are two independent tumor predictors that are of great significance for the prognostic prediction of other tumors, and their expression levels may be related to the prognosis of glioma patients. Methods: using Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), the Chinese Glioma Genome Atlas (CGGA), cBioPortal, LinkedOmics, and other databases, 693 glioma patients were screened to analyze the relationship between EMP3 and CHI3L1 expression and prognosis in glioma patients. Results: low-grade glioma patients with a low expression of EMP3/CHI3L1 had a better prognosis, and the combination of EMP3/CHI3L1 is a new predictor for glioma patients. Conclusion: We used the TCGA and CGGA databases to analyze the effect of EMP3 and CHI3L1 expression on the prognosis of glioma patients and their correlation with gene expression using bioinformation analysis. The results showed that low-grade glioma patients with a low expression of EMP3 and CHI3L1 had a better prognosis, and EMP3 and CHI3L1 co-expression genes were correlated. The combination of these two factors could be a new prognostic index for glioma patients.

show abstract

Establishment of a nomogram with EMP3 for predicting clinical outcomes in patients with glioma: A bi‐center study

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 6 publications

References 65 publications

EMP3 as a prognostic biomarker correlates with EMT in GBM

EMP3 as a prognostic biomarker correlates with EMT in GBM

Identification of a pyroptosis-related prognosis gene signature and its relationship with an immune microenvironment in gliomas

Epithelial Membrane Protein-3 and Chitinase-3-like Protein-1 as New Prognostic Predictors of Glioma, a Two-Gene Study

Contact Info

Product

Resources

About